抗癌药-话题@MedSci

#抗癌药#

351篇内容 | 5648人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1314686, encodeId=636a131468637, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=NICE推荐抗癌药“海乐卫”（Halaven）用于晚期乳腺癌的治疗, objectType=article, longId=83408, objectId=86f0834083a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86f0834083a, replyNumber=0, likeNumber=68, createdTime=2016-12-03, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86f0834083a, moduleTitle=NICE推荐抗癌药“海乐卫”（Halaven）用于晚期乳腺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86f0834083a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314685, encodeId=e0a4131468515, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=多篇突破性研究直击抗癌药物新发现, objectType=article, longId=81900, objectId=936a8190012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936a8190012, replyNumber=0, likeNumber=71, createdTime=2016-11-08, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936a8190012, moduleTitle=多篇突破性研究直击抗癌药物新发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936a8190012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314684, encodeId=00171314684d1, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=JMC：科学家成功改造抗癌药物结构增强血脑屏障穿透能力, objectType=article, longId=80693, objectId=094c80693d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=094c80693d6, replyNumber=0, likeNumber=62, createdTime=2016-10-24, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=094c80693d6, moduleTitle=JMC：科学家成功改造抗癌药物结构增强血脑屏障穿透能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=094c80693d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314683, encodeId=bb81131468371, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=PNAS：让抗癌药“歪打正着”的研发策略, objectType=article, longId=79807, objectId=a268e980777, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a268e980777, replyNumber=0, likeNumber=47, createdTime=2016-10-13, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a268e980777, moduleTitle=PNAS：让抗癌药“歪打正着”的研发策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a268e980777)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314682, encodeId=316c131468226, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, objectType=article, longId=79539, objectId=ef32e9539e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef32e9539e8, replyNumber=0, likeNumber=64, createdTime=2016-10-10, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef32e9539e8, moduleTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef32e9539e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314681, encodeId=a4e113146818d, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决, objectType=article, longId=79383, objectId=2781e9383a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2781e9383a5, replyNumber=0, likeNumber=82, createdTime=2016-10-08, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2781e9383a5, moduleTitle=重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2781e9383a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314680, encodeId=fd551314680d1, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, objectType=article, longId=78707, objectId=88a4e870731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a4e870731, replyNumber=0, likeNumber=54, createdTime=2016-09-29, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a4e870731, moduleTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a4e870731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314679, encodeId=82b113146e9c5, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=【专访】鲁先平：十年磨一剑，终于迎来中国自己的原创抗癌药, objectType=article, longId=78538, objectId=2921e853814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2921e853814, replyNumber=0, likeNumber=62, createdTime=2016-09-28, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2921e853814, moduleTitle=【专访】鲁先平：十年磨一剑，终于迎来中国自己的原创抗癌药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2921e853814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=Cell：剑桥革命性新技术能更快筛选抗癌药物并公开数据, objectType=article, longId=78478, objectId=29aee847860, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29aee847860, replyNumber=0, likeNumber=78, createdTime=2016-09-28, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29aee847860, moduleTitle=Cell：剑桥革命性新技术能更快筛选抗癌药物并公开数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29aee847860)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314676, encodeId=f90713146e6bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）, objectType=article, longId=76568, objectId=80e0e6568b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e0e6568b4, replyNumber=0, likeNumber=73, createdTime=2016-09-04, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e0e6568b4, moduleTitle=第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e0e6568b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314677, encodeId=3fb713146e7c6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=76572, objectId=8bfbe657216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bfbe657216, replyNumber=0, likeNumber=54, createdTime=2016-09-04, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bfbe657216, moduleTitle=精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bfbe657216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314675, encodeId=36ed13146e55a, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=喜讯！辉瑞口服靶向抗癌药Xalkori（克唑替尼）获英国NICE推荐，一线治疗ALK阳性肺癌, objectType=article, longId=75774, objectId=c8c4e5774d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8c4e5774d2, replyNumber=0, likeNumber=68, createdTime=2016-08-25, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8c4e5774d2, moduleTitle=喜讯！辉瑞口服靶向抗癌药Xalkori（克唑替尼）获英国NICE推荐，一线治疗ALK阳性肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8c4e5774d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314673, encodeId=6dcc13146e334, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, objectType=article, longId=74627, objectId=2d0ae462726, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0ae462726, replyNumber=0, likeNumber=62, createdTime=2016-08-08, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0ae462726, moduleTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0ae462726)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314674, encodeId=aab113146e4b2, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据, objectType=article, longId=74630, objectId=4456e46306b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4456e46306b, replyNumber=0, likeNumber=66, createdTime=2016-08-08, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4456e46306b, moduleTitle=卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4456e46306b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314672, encodeId=115213146e26c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, objectType=article, longId=74521, objectId=f237e452185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f237e452185, replyNumber=0, likeNumber=79, createdTime=2016-08-07, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f237e452185, moduleTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f237e452185)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314671, encodeId=244313146e19d, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=抗癌药有望治疗帕金森？诺华将开展Tasigna 帕金森症临床试验, objectType=article, longId=73843, objectId=91fde384368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91fde384368, replyNumber=0, likeNumber=69, createdTime=2016-07-28, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91fde384368, moduleTitle=抗癌药有望治疗帕金森？诺华将开展Tasigna 帕金森症临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91fde384368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314670, encodeId=b6bb13146e07e, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=自主研发的“抗癌药”缘何“远嫁”美国, objectType=article, longId=72847, objectId=12d0e284748, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12d0e284748, replyNumber=0, likeNumber=66, createdTime=2016-07-16, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12d0e284748, moduleTitle=自主研发的“抗癌药”缘何“远嫁”美国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12d0e284748)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314669, encodeId=cf9713146694a, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=峰回路转！吉利德重磅抗癌药Zydelig通过欧洲药品管理局安全审查！, objectType=article, longId=72753, objectId=f303e27534d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f303e27534d, replyNumber=0, likeNumber=52, createdTime=2016-07-15, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f303e27534d, moduleTitle=峰回路转！吉利德重磅抗癌药Zydelig通过欧洲药品管理局安全审查！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f303e27534d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314668, encodeId=b4b4131466803, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, objectType=article, longId=72295, objectId=f93de22957a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93de22957a, replyNumber=0, likeNumber=73, createdTime=2016-07-09, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93de22957a, moduleTitle=欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93de22957a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314667, encodeId=8b9a131466ee0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, objectType=article, longId=71847, objectId=9b2ae184708, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b2ae184708, replyNumber=0, likeNumber=58, createdTime=2016-07-01, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b2ae184708, moduleTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b2ae184708)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗癌药

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

NICE推荐抗癌药“海乐卫”（Halaven）用于晚期乳腺癌的治疗

2016-12-03

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

多篇突破性研究直击抗癌药物新发现

2016-11-08

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

JMC：科学家成功改造抗癌药物结构增强血脑屏障穿透能力

2016-10-24

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

PNAS：让抗癌药“歪打正着”的研发策略

2016-10-13

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发

2016-10-10

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决

2016-10-08

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保

2016-09-29

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

【专访】鲁先平：十年磨一剑，终于迎来中国自己的原创抗癌药

2016-09-28

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

Cell：剑桥革命性新技术能更快筛选抗癌药物并公开数据

2016-09-28

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）

2016-09-04

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）

2016-09-04

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

喜讯！辉瑞口服靶向抗癌药Xalkori（克唑替尼）获英国NICE推荐，一线治疗ALK阳性肺癌

2016-08-25

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）

2016-08-08

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据

2016-08-08

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）

2016-08-07

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

抗癌药有望治疗帕金森？诺华将开展Tasigna 帕金森症临床试验

2016-07-28

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

自主研发的“抗癌药”缘何“远嫁”美国

2016-07-16

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

峰回路转！吉利德重磅抗癌药Zydelig通过欧洲药品管理局安全审查！

2016-07-15

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗

2016-07-09

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功

2016-07-01

科室
- - 订阅+
  - 更多科室
工具
服务